A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma
Yoon Jung Jang, Sang Moo Lim, Inki Lee, Byung Hyun Byun, Ilhan Lim, Byung Il Kim, Chang Woon Choi, Seung-Sook Lee, Sung Hyun Yang, Im Il Na, Hyo-Rak Lee, Dong-Yeop Shin, Hye Jin Kang · 2023
Read A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma by Yoon Jung Jang, Sang Moo Lim, Inki Lee, Byung Hyun Byun, Ilhan Lim, Byung Il Kim, Chang Woon Choi, Seung-Sook Lee, Sung Hyun Yang, Im Il Na, Hyo-Rak Lee, Dong-Yeop Shin, Hye Jin Kang (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10714876.txt.
Description
Yoon Jung Jang and co-authors report a phase II trial of a radioactive form of the drug rituximab, in a 2023 study. The drug was given to people with marginal zone lymphoma. Their cancer had come back or resisted prior care. This kind of radio-linked treatment is a rare option for B-cell blood cancers.
Patients first received a plain dose of the drug, then the radioactive dose. Ten patients took part, with a median age in the late fifties. Slow enrollment cut the trial short. The main goal was the share whose tumors shrank, with side effects and survival also tracked. The small size limits what the trial can show, but readers get a careful record for a hard-to-treat group.
Catalog record
| CREATOR | Yoon Jung Jang, Sang Moo Lim, Inki Lee, Byung Hyun Byun, Ilhan Lim, Byung Il Kim, Chang Woon Choi, Seung-Sook Lee, Sung Hyun Yang, Im Il Na, Hyo-Rak Lee, Dong-Yeop Shin, Hye Jin Kang |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |